Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $9 from $12 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Arcturus Therapeutics Earnings Call: Progress Amid Challenges
- Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler
- Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress
- Arcturus Therapeutics reports Q3 EPS (49c), consensus (80c)